New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer

Qiang, Huiping; Chang, Qing; Xu, Jianlin; Qian, Jialin; Zhang, Yanwei; Lei, Yuqiong; Han, Baohui; Chu, Tianqing

doi:10.1007/s00432-020-03129-6

Cited by 60 publications

(43 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the 1970s it was demonstrated that in case of acute lymphocytic leukemia [46] and Hodgkin's lymphoma [47] combination chemotherapy could be more effective than using a single drug or two drugs one at a time, in sequence. While single-drug chemotherapy may still be better for some cancers, in the last decade combination of chemotherapy medications has been adopted for the treatment of many cancer types and has greatly increased survival rates [48][49][50]. The benefits of using combination chemotherapy rather than single agents include decreased occurrence of resistance and sometimes (but not always) reduced intensity of side effects due to the lower doses of two drugs instead of a high dose of one drug.…”

Section: Discussionmentioning

confidence: 99%

A New Hybrid δ-Lactone Induces Apoptosis and Potentiates Anticancer Activity of Taxol in HL-60 Human Leukemia Cells

et al. 2020

View full text Add to dashboard Cite

In the search for new drug candidates, researchers turn to natural substances isolated from plants which may be either used directly or may serve as a source for chemical modifications. An interesting strategy in the design of novel anticancer agents is based on the conjugation of two or more biologically active structural motifs into one hybrid compound. In this study, we investigated the anticancer potential of 4-benzyl-5,7-dimethoxy-4-methyl-3-methylidene-3,4-dihydro-2H-chroman-2-one (DL-247), a new hybrid molecule combining a chroman-2-one skeleton with an exo-methylidene bond conjugated with a carbonyl group, in human myeloid leukemia HL-60 cell line. The cytotoxicity of the new compound was tested using MTT assay. The effect of DL-247 on cell proliferation and apoptosis induction were studied by flow cytometry, fluorometric assay and ELISA analysis. DL-247 displayed high cytotoxic activity (IC50 = 1.15 µM, after 24 h incubation), significantly inhibited cell proliferation and induced apoptosis by both, the intrinsic and extrinsic pathways. A combination of DL-247 with taxol exhibited a strong synergistic effect on DNA damage generation, apoptosis induction and inhibition of cell growth.

show abstract

Section: Discussionmentioning

confidence: 99%

A New Hybrid δ-Lactone Induces Apoptosis and Potentiates Anticancer Activity of Taxol in HL-60 Human Leukemia Cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Targeted therapy is recommended for patients with advanced lung cancer with sensitive mutations such as EGFR, anaplastic lymphoma kinase fusion (ALK), and ROS1 fusion . Studies show that patients receiving targeted therapy in combination with antivascular therapy, chemotherapy, or immunotherapy may experience enhanced antitumor effects . However, in the current epidemic situation, being vigilant about a possible increase in adverse events due to combination therapy is necessary .…”

Section: Recommendations Of Individualized Medical Treatment Strategiesmentioning

confidence: 99%

Recommendations of individualized medical treatment and common adverse events management for lung cancer patients during the outbreak of COVID‐19 epidemic

et al. 2020

View full text Add to dashboard Cite

Since its outbreak in December 2019 in China, the novel coronavirus disease has rapidly spread and affected several countries. It has resulted in a difficult situation for cancer patients owing to the risks of the epidemic situation outbreak as well as cancer. Patients with cancer are more likely than the general population to contract COVID-19 because of the systemic immunosuppressive status caused by malignant diseases or anticancer treatment. Lung cancer has the highest morbidity and mortality in China and the world. Most patients with lung cancer are smokers with poor underlying lung conditions and low immunity, thus it is vital to protect them from epidemic diseases during cancer treatment. It is necessary to provide individualized medical treatment and management of treatment-related adverse events for patients with lung cancer based on patients' conditions and regional epidemic patterns. Key pointsSignificant findings of the study During the outbreak of COVID-19, taking patients' conditions and regional epidemic patterns into consideration, providing appropriate individualized treatment strategies for lung cancer patients with different stages is an urgent requirement. What this study adds Based on the characteristics of lung cancer, this article aims to provide recommendations and suggestions of individualized treatment strategies and management of common adverse events for patients with lung cancer during the epidemic period of COVID-19.

show abstract

“…Thus, the development of novel strategies on anti-invasion and antimetastatic treatment for NSCLC are urgently required. The complex pathogenesis of NSCLC indicates that the combination of two or more antitumor agents possessing different molecular mechanisms may be a therapeutic option for efficient treatment (7).…”

Section: Introductionmentioning

confidence: 99%

Combination treatment of gemcitabine and sorafenib exerts a synergistic inhibitory effect on non‑small cell lung cancer in�vitro and in�vivo via the epithelial‑to‑mesenchymal transition process

et al. 2020

View full text Add to dashboard Cite

Standard chemotherapy is commonly used in clinical practice for the treatment of non-small cell lung cancer (NSCLC). However, its therapeutic efficacy remains low. Combination therapy for cancer treatment has attracted attention in recent years. The present study aimed to investigate the antitumor effect of the combination treatment with gemcitabine and sorafenib on NSCLC in vitro and in vivo, and to determine its underlying molecular mechanisms. The anti-NSCLC effects of combination therapy were analyzed by flow cytometry analysis, MTT, western blotting, reverse transcription-quantitative PCR, wound healing and Transwell invasion assays. A549 cells subjected to combination treatment with gemcitabine and sorafenib demonstrated a more irregular cellular morphology and lower cell viability compared with the monotherapy groups. Combination of gemcitabine and sorafenib significantly induced cell cycle arrest and apoptosis in A549 cells. Additionally, combination therapy was demonstrated to restrain the migration and invasion of tumor cells by suppressing epithelial-to-mesenchymal transition (EMT) of A549 cells. In vivo analyses confirmed that co-treatment with gemcitabine and sorafenib decreased NSCLC tumor growth and tumor weight in nude mice. Taken together, the results of the present study suggested that combination treatment with gemcitabine and sorafenib exerted a synergistic inhibitory effect on NSCLC in vitro and in vivo via the EMT process.Abbreviations: NSCLC, non-small cell lung cancer; EMT, epithelial-to-mesenchymal transition

show abstract

New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer

Cited by 60 publications

References 75 publications

A New Hybrid δ-Lactone Induces Apoptosis and Potentiates Anticancer Activity of Taxol in HL-60 Human Leukemia Cells

A New Hybrid δ-Lactone Induces Apoptosis and Potentiates Anticancer Activity of Taxol in HL-60 Human Leukemia Cells

Recommendations of individualized medical treatment and common adverse events management for lung cancer patients during the outbreak of COVID‐19 epidemic

Combination treatment of gemcitabine and sorafenib exerts a synergistic inhibitory effect on non‑small cell lung cancer in�vitro and in�vivo via the epithelial‑to‑mesenchymal transition process

Contact Info

Product

Resources

About